Previous 10 | Next 10 |
You've probably heard of the buy-low-and-sell-high investment strategy, but what about buying high and selling even higher? After sliding throughout most of 2022, shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) jumped nearly 300% higher on Dec. 19, 2022. This is a clinical-stage dru...
Summary Like an early Christmas/Hanukkah present, Madrigal shares rallied over 268% in one session due to the positive MAESTRO-NASH data. The shares continue to move in the ensuing day. Coupled with the strong Phase 3 (MAESTRO-NAFLD-1) results, Madrigal is poised to file a marketing app...
This week was going down as one to remember for Madrigal Pharmaceuticals (NASDAQ: MDGL) . According to data compiled by S&P Global Market Intelligence , the biotech's shares were an eye-watering 350% higher week to date, as of Thursday's market close. Biotechs tend to pop like tha...
Summary ETNB went down after Madrigal's success. It has a NASH molecule with a different mechanism of action. It has produced solid data. 89Bio ( ETNB ) is one of those NASH stocks that didn’t do too well on Madrigal’s ( MDGL ) success. It fell 30% on...
Summary On Monday, Madrigal Pharmaceuticals announced a best-case dataset from its phase 3 trial in NASH. This opens up a Huge market for the company. Madrigal Pharmaceuticals stock is up 4x: what you should do now. I have been bullish on Madrigal ( MDGL ) since 20...
Summary Madrigal Pharmaceuticals announced positive top-line results from their phase three trial evaluating Resmetirom as a treatment for NASH fibrosis on Monday, sending shares up by almost 300 percent since. Both the 80 milligram and 100 milligram dosages achieved statistical signifi...
Update: Adds analyst comments from Goldman Sachs, Truist Madrigal Pharmaceuticals ( NASDAQ: MDGL ) closed up 268% in Monday trading after releasing late-stage results on resmetirom for nonalcoholic steatohepatitis ( NASH ) and liver fibrosis. NASH resu...
Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) had skyrocketed by 243.7% as of 11:11 a.m. ET on Monday. The huge gain came after the company announced positive results from a phase 3 clinical study evaluating its experimental drug resmetirom as a treatment for nonalcoholic steatohepati...
The stock market has been on edge over the past several days, and Monday didn't seem to bring a lot of clarity in a difficult economy. The Nasdaq Composite (NASDAQINDEX: ^IXIC) kept declining shortly after the opening bell on Monday morning, failing to recapture any of its losses from lat...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Viking Therapeutics (NASDAQ: VKTX ) stock is taking off on Monday without any news from the biopharmaceutical company. Instead, it looks like holders of NKTX stock have Madrigal Pharmaceutica...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...